Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis (CARPAPA)

Association pour la Recherche Clinique et Immunologique

Status: Completed

Conditions: Psoriasis; Arthritis, Psoriatic

Treatments: Diagnostic Test: Serum anti-CarP antibodies detection

Study type: Interventional

Funder types: Other

Identifiers

NCT04173039

18071A0003

Details and patient eligibility

About

Anti-carbamylated protein (anti-CarP) antibodies are present in approximately one-fourth of the patients who are seronegative for both rheumatoid factor and anti-citrullinated protein antibody and who may therefore have psoriatic arthritis. The investigators hypothesized that detection of anti-CarP antibodies in serum may be useful for diagnosis of psoriatic arthritis.

Enrollment: 300 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• "Controls" : Patients with a psoriasis confirmed by a dermatologist and with absence of psoriatic arthritis confirmed by a rheumatologist.
• "Cases" : Patients with psoriatic arthritis fulfilling the classification criteria for psoriatic arthritis (CASPAR), with a diagnosis confirmed by a rheumatologist and associated with personal or familial psoriasis.

Exclusion criteria

• "Controls": Presence of any chronic rheumatic inflammatory disease such as psoriatic arthritis.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

300 participants in 2 patient groups

Controls

Other group

Description:

Patients with psoriasis and without psoriatic arthritis.

Treatment:

Diagnostic Test: Serum anti-CarP antibodies detection

Cases

Other group

Description:

Patients with psoriatic arthritis and with personal or familial psoriasis.

Treatment:

Diagnostic Test: Serum anti-CarP antibodies detection